Eliquis Tablet, Film Coated
Product Images NDC 55154-0612

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Eliquis (NDC 55154-0612). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Apixaban Chemical Structure (Apixaban Struct)

Chemical structure of apixaban, the active ingredient in ELIQUIS. The diagram shows the molecular arrangement including rings and functional groups characteristic of this anticoagulant drug.*

FDA Label Image

D9f4bccb Df6a 43d3 Ad27 F9d0682f054c 00

Label for ELIQUIS (apixaban) tablets 5 mg. The label states each tablet contains 5 mg apixaban and specifies Rx only. It includes storage instructions, manufacturer and distributor information, and warnings to keep out of reach of children. The label also shows barcodes and indicates the package contains approximately 2040 tablets.*

FDA Label Image

D9f4bccb Df6a 43d3 Ad27 F9d0682f054c 01

Label for ELIQUIS tablets 5 mg (apixaban) in a 10-tablet unit dose package. The label includes storage instructions, a warning that the packaging is not child-resistant and intended for institutional use only, and advises dispensing with a medication guide. It lists Bristol-Myers Squibb Company and Pfizer Inc as marketers, production in Switzerland, and distribution by Cardinal Health.*

FDA Label Image

D9f4bccb Df6a 43d3 Ad27 F9d0682f054c 02

Label for ELIQUIS 2.5 mg tablets containing apixaban as the active ingredient. The film-coated oral tablets are prescription-only and labeled by Cardinal Health 107, LLC. The label includes dosage information, storage instructions, warnings to keep out of reach of children, and barcode details.*

FDA Label Image

D9f4bccb Df6a 43d3 Ad27 F9d0682f054c 03

The image shows a carton label for ELIQUIS Tablets 2.5 mg, containing apixaban. The label indicates a package of 10 film-coated tablets for oral use. It includes dosage information, storage conditions, warnings, and marketing details by Bristol-Myers Squibb Company, Pfizer Inc, and distribution by Cardinal Health. A barcode and NDC number 55154-0612-0 are present.*

FDA Label Image

Aristotle Forest Plot (Eliquis Clin Forest Fig5)

A forest plot comparing the number of events and hazard ratios between apixaban and warfarin treatments across various patient subgroups. The horizontal axis measures hazard ratios with markers indicating relative risk and 95% confidence intervals for each subgroup, illustrating the comparative effectiveness of apixaban versus warfarin in terms of event rates.*

FDA Label Image

Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)

A forest plot comparing hazard ratios between apixaban and warfarin in various patient subgroups. The chart displays the number of events and patients per group, with confidence intervals for hazard ratios, visually showing which drug performs better across categories like age, sex, weight, diabetes mellitus, geographic region, and kidney function measures.*

FDA Label Image

Aristotle Kaplan-meier Curve (Eliquis Km Fig4)

A Kaplan-Meier curve displaying the proportion of subjects experiencing stroke or systemic embolism over 36 months, comparing ELIQUIS (apixaban) and Warfarin. The graph includes event counts, number of subjects at risk at select time points, and statistical measures (P-value 0.0114; hazard ratio 0.79).*

FDA Label Image

Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)

A forest plot chart showing the fold change and 90% confidence intervals in pharmacokinetic parameters (Cmax and AUC) of ELIQUIS (apixaban) when interacting with various drugs. The chart lists combined P-gp and strong CYP3A4 inhibitors (ketoconazole 400 mg, clarithromycin 500 mg), other CYP3A4 and P-gp inhibitors (diltiazem 360 mg, naproxen 500 mg), and a combined P-gp and strong CYP3A4 inducer (rifampin 600 mg). The x-axis represents change relative to reference with values ranging from 0.5 to 2.0.*

FDA Label Image

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)

A clinical pharmacokinetic chart displaying fold changes with 90% confidence intervals for Cmax and AUC of apixaban in various population subgroups, including different levels of renal impairment, age groups, body weights, and hepatic impairment. The chart also includes associated dosing recommendations for each subgroup, mostly indicating no dose adjustment except for moderate hepatic impairment where no dosing recommendation is provided.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.